Roles of the androgen–Androgen receptor system in vascular angiogenesis

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 3, 2016, Pages 257-265

  Yoshida, Sumiko ^a   Ikeda, Yasumasa ^a   Aihara, Ken Ichi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Androgen; Androgen receptor; Angiogenesis; Cardiovascular disease; Vascular endothelial growth factor

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DOXORUBICIN; NITRIC OXIDE; VASCULOTROPIN; ANDROGEN;

ANGIOGENESIS; APOPTOSIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CELL ADHESION; CELL PROLIFERATION; GENE INTERACTION; HUMAN; ISCHEMIA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; CARDIOVASCULAR DISEASE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY;

ANDROGENS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ANDROGEN;

EID: 84959258899     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.31047     Document Type: Review

References (105)

1. Liu PY, Death AK, Handelsman DJ: Androgens and cardiovascular disease. Endocr Rev, 2003; 24: 313-340
2. Kalin MF, Zumoff B: Sex hormones and coronary disease: a review of the clinical studies. Steroids, 1990; 55: 330-352
3. Criqui MH: Epidemiology of atherosclerosis: an updated overview. Am J Cardiol, 1986; 57: 18C-23C
4. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. JGerontol A Biol Sci Med Sci, 2005; 60: 1451-1457
5. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM: Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebocontrolled trials. Mayo Clin Proc, 2007; 82: 29-39
6. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM: Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab, 2010; 95: 2560-2575
7. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB: Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab, 2002; 87: 589-598
8. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab, 2001; 86: 724-731
9. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC: Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol, 2005; 48: 1-4
10. O'Connell MD, Wu FC: Androgen effects on skeletal muscle: implications for the development and management of frailty. Asian J Androl, 2014; 16: 203-212
11. Mohr BA, Bhasin S, Link CL, O'Donnell AB, McKinlay JB: The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol, 2006; 155: 443-452
12. Michalakis K, Goulis DG, Vazaiou A, Mintziori G, Polymeris A, Abrahamian-Michalakis A: Obesity in the ageing man. Metabolism, 2013; 62: 1341-1349
13. Haring R, Baumeister SE, Volzke H, Dorr M, Felix SB, Kroemer HK, Nauck M, Wallaschofski H: Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil, 2011; 18: 86-96
14. Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 2006; 295: 1288-1299
15. Kupelian V, Chiu GR, Araujo AB, Williams RE, Clark RV, McKinlay JB: Association of sex hormones and C-reactive protein levels in men. Clin Endocrinol (Oxf), 2010; 72: 527-533
16. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N: Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk). Prospective Population Study. Circulation, 2007; 116: 2694-2701
17. Laughlin GA, Barrett-Connor E, Bergstrom J: Lowserum testosterone and mortality in older men. J Clin Endocrinol Metab, 2008; 93: 68-75
18. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellstrom D, Ohlsson C: Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab, 2009; 94: 2482-2488
19. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y: Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis, 2010; 210: 232-236
20. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS: Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 2010; 96: 1821-1825
21. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA: Clinical review: Endogenous testosterone and mortality in men: a systematic review and metaanalysis. J Clin Endocrinol Metab, 2011; 96: 3007-3019
22. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 2004; 27: 1036-1041
23. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA: Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care, 2007; 30: 234-238
24. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S: Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A, 2003; 100: 9416-9421
25. Ikeda Y, Aihara K, Akaike M, Sato T, Ishikawa K, Ise T, Yagi S, Iwase T, Ueda Y, Yoshida S, Azuma H, Walsh K, Tamaki T, Kato S, Matsumoto T: Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol, 2010; 24: 1338-1348
26. Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, Suzaki Y, Izawa Y, Fujimura M, Hashizume S, Kato M, Yagi S, Tamaki T, Kawano H, Matsumoto T, Azuma H, Kato S, Matsumoto T: Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem, 2005; 280: 29661-29666
27. Ikeda Y, Aihara K, Yoshida S, Sato T, Yagi S, Iwase T, Sumitomo Y, Ise T, Ishikawa K, Azuma H, Akaike M, Kato S, Matsumoto T: Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrinology, 2009; 150: 2857-2864
28. Mooradian AD, Morley JE, Korenman SG: Biological actions of androgens. Endocr Rev, 1987; 8: 1-28
29. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell, 1995; 83: 835-839
30. Lin AL, McGill HC, Jr. , Shain SA: Hormone receptors of the baboon cardiovascular system. Biochemical char-acterization of myocardial cytoplasmic androgen receptors. Circ Res, 1981; 49: 1010-1016
31. Horwitz KB, Horwitz LD: Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest, 1982; 69: 750-758
32. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, Morel L: Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem, 2004; 279: 14579-14586
33. Heinlein CA, Chang C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol, 2002; 16: 2181-2187
34. Jones RD, Pugh PJ, Jones TH, Channer KS: The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol, 2003; 138: 733-744
35. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G: Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A, 2001; 98: 3589-3593
36. Yoshida S, Aihara K, Ikeda Y, Sumitomo-Ueda Y, Uemoto R, Ishikawa K, Ise T, Yagi S, Iwase T, Mouri Y, Sakari M, Matsumoto T, Takeyama K, Akaike M, Matsumoto M, Sata M, Walsh K, Kato S, Matsumoto T: Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation, 2013; 128: 60-71
37. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E: Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab, 1997; 82: 682-685
38. Svartberg J, von Muhlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R: Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol, 2004; 150: 65-71
39. Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ: Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab, 2006; 290: E234-242
40. Dockery F, Bulpitt CJ, Donaldson M, Fernandez S, Rajkumar C: The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc, 2003; 51: 1627-1632
41. Yaron M, Greenman Y, Rosenfeld JB, Izkhakov E, Limor R, Osher E, Shenkerman G, Tordjman K, Stern N: Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol, 2009; 160: 839-846
42. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS: Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 2000; 21: 890-894
43. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: Arandomized, double-blind, placebo-controlled study. Circulation, 2000; 102: 1906-1911
44. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, McGill CC, Heller GV: Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J, 2002; 143: 249-256
45. Tivesten A, Mellstrom D, Jutberger H, Fagerberg B, Lernfelt B, Orwoll E, Karlsson MK, Ljunggren O, Ohlsson C: Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol, 2007; 50: 1070-1076
46. Price JF, Leng GC: Steroid sex hormones for lower limb atherosclerosis. Cochrane Database Syst Rev, 2002; CD000188
47. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT: Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation, 2004; 109: 2074-2079
48. Yoshida S, Aihara K, Azuma H, Uemoto R, Sumitomo- Ueda Y, Yagi S, Ikeda Y, Iwase T, Nishio S, Kawano H, Miki J, Yamada H, Hirata Y, Akaike M, Sata M, Matsumoto T: Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis, 2010; 212: 310-315
49. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab, 2002; 87: 3632-3639
50. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE: Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol, 2003; 157: 25-31
51. Demirbag R, Yilmaz R, Ulucay A, Unlu D: The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res, 2005; 31: 335- 344
52. Makinen J, Jarvisalo MJ, Pollanen P, Perheentupa A, Irjala K, Koskenvuo M, Makinen J, Huhtaniemi I, Raitakari OT: Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol, 2005; 45: 1603-1608
53. Svartberg J, von Muhlen D, Mathiesen E, Joakimsen O, Bonaa KH, Stensland-Bugge E: Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med, 2006; 259: 576-582
54. Jin H, Lin J, Fu L, Mei YF, Peng G, Tan X, Wang DM, Wang W, Li YG: Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol, 2007; 85: 246-251
55. Jin H, Qiu WB, Mei YF, Wang DM, Li YG, Tan XR: Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells. Asian J Androl, 2009; 11: 266-271
56. Jin H, Wang DY, Mei YF, Qiu WB, Zhou Y, Wang DM, Tan XR, Li YG: Mitogen-activated protein kinases pathway is involved in physiological testosterone-induced tissue factor pathway inhibitor expression in endothelial cells. Blood Coagul Fibrinolysis, 2010; 21: 420-424
57. Kelly DM, Jones TH: Testosterone: a vascular hormone in health and disease. J Endocrinol, 2013; 217: R47-71
58. Yu J, Akishita M, Eto M, Koizumi H, Hashimoto R, Ogawa S, Tanaka K, Ouchi Y, Okabe T: Src kinasemediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. Biochem Biophys Res Commun, 2012; 424: 538-543
59. Yu J, Akishita M, Eto M, Ogawa S, Son BK, Kato S, Ouchi Y, Okabe T: Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/ akt pathway. Endocrinology, 2010; 151: 1822-1828
60. Goglia L, Tosi V, Sanchez AM, Flamini MI, Fu XD, Zullino S, Genazzani AR, Simoncini T: Endothelial regulation of eNOS, PAI-1 and t-PA by testosterone and dihydrotestosterone in vitro and in vivo. Mol Hum Reprod, 2010; 16: 761-769
61. Koizumi H, Yu J, Hashimoto R, Ouchi Y, Okabe T: Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Lett, 2010; 584: 2440-2444
62. Campelo AE, Cutini PH, Massheimer VL: Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol. Steroids, 2012; 77: 1033-1040
63. Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS: Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol, 2011; 300: H1210-1221
64. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA: Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab, 2002; 87: 176-181
65. Nakamura Y, Suzuki T, Igarashi K, Kanno J, Furukawa T, Tazawa C, Fujishima F, Miura I, Ando T, Moriyama N, Moriya T, Saito H, Yamada S, Sasano H: PTOV1: a novel testosterone-induced atherogenic gene in human aorta. J Pathol, 2006; 209: 522-531
66. Ling S, Dai A, Williams MR, Myles K, Dilley RJ, Komesaroff PA, Sudhir K: Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology, 2002; 143: 1119-1125
67. Death AK, McGrath KC, Sader MA, Nakhla S, Jessup W, Handelsman DJ, Celermajer DS: Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factorkappaB- dependent pathway. Endocrinology, 2004; 145: 1889-1897
68. Nheu L, Nazareth L, Xu GY, Xiao FY, Luo RZ, Komesaroff P, Ling S: Physiological effects of androgens on human vascular endothelial and smooth muscle cells in culture. Steroids, 2011; 76: 1590-1596
69. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL: Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab, 2006; 91: 546-554
70. Hatakeyama H, Nishizawa M, Nakagawa A, Nakano S, Kigoshi T, Uchida K: Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule- 1 expression in human aortic endothelial cells. FEBS Lett, 2002; 530: 129-132
71. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev, 2004; 56: 549-580
72. Carmeliet P: Angiogenesis in life, disease and medicine. Nature, 2005; 438: 932-936
73. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992; 359: 843-845
74. Sieveking DP, Chow RW, Ng MK: Androgens, angiogenesis and cardiovascular regeneration. Curr Opin Endocrinol Diabetes Obes, 2010; 17: 277-283
75. Sieveking DP, Lim P, Chow RW, Dunn LL, Bao S, McGrath KC, Heather AK, Handelsman DJ, Celermajer DS, Ng MK: A sex-specific role for androgens in angiogenesis. J Exp Med, 2010; 207: 345-352
76. Sjogren M, Alkemade A, Mittag J, Nordstrom K, Katz A, Rozell B, Westerblad H, Arner A, Vennstrom B: Hypermetabolism in mice caused by the central action of an unliganded thyroid hormone receptor alpha 1. EMBO J, 2007; 26: 4535-4545
77. Merot Y, Ferriere F, Gailhouste L, Huet G, Percevault F, Saligaut C, Flouriot G: Different outcomes of unliganded and liganded estrogen receptor-alpha on neurite outgrowth in PC12 cells. Endocrinology, 2009; 150: 200-211
78. Alimirah F, Vaishnav A, McCormick M, Echchgadda I, Chatterjee B, Mehta RG, Peng X: Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription. Mol Cell Biochem, 2010; 342: 143-150
79. Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol, 2007; 8: 464-478
80. Eichmann A, Simons M: VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol, 2012; 24: 188-193
81. Shiojima I, Walsh K: Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res, 2002; 90: 1243-1250
82. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest, 1998; 101: 2567-2578
83. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A: Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodi-lation in men with erectile dysfunction. Clin Endocrinol (Oxf), 2000; 53: 517-522
84. Lecce L, Lam YT, Lindsay LA, Yuen SC, Simpson PJ, Handelsman DJ, Ng MK: Aging impairs VEGF-mediated, androgen-dependent regulation of angiogenesis. Mol Endocrinol, 2014; 28: 1487-1501
85. Ota H, Akishita M, Akiyoshi T, Kahyo T, Setou M, Ogawa S, Iijima K, Eto M, Ouchi Y: Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT 1. PLoS One, 2012; 7: e29598
86. Maizel J, Xavier S, Chen J, Lin CH, Vasko R, Goligorsky MS: Sirtuin 1 ablation in endothelial cells is associated with impaired angiogenesis and diastolic dysfunction. Am J Physiol Heart Circ Physiol, 2014; 307: H1691-1704
87. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol, 2006; 7: 359-371
88. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell, 2001; 104: 719-730
89. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ: Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem, 2003; 278: 42992-43000
90. Schlessinger J: New roles for Src kinases in control of cell survival and angiogenesis. Cell, 2000; 100: 293-296
91. Reed MJ, Karres N, Eyman D, Edelberg J: Endothelial precursor cells. Stem Cell Rev, 2007; 3: 218-225
92. King TF, McDermott JH: Endothelial progenitor cells and cardiovascular disease. J Stem Cells, 2014; 9: 93-106
93. Hristov M, Weber C: Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res, 2008; 58: 148-151
94. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, Garolla A: Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab, 2006; 91: 4599-4602
95. Foresta C, Zuccarello D, De Toni L, Garolla A, Caretta N, Ferlin A: Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf), 2008; 68: 284-289
96. Liu R, Ding L, Yu MH, Wang HQ, Li WC, Cao Z, Zhang P, Yao BC, Tang J, Ke Q, Huang TZ: Effects of dihydrotestosterone on adhesion and proliferation via PI3-K/Akt signaling in endothelial progenitor cells. Endocrine, 2014; 46: 634-643
97. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC: Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediatefrail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab, 2010; 95: 639-650
98. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S: Adverse events associated with testosterone administration. N Engl J Med, 2010; 363: 109-122
99. Carson CC, 3rd, Rosano G: Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med, 2012; 9: 54-67
100. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, Ljunggren O, Vandenput L, Mellstrom D, Tivesten A: High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol, 2011; 58: 1674-1681
101. Jones TH, Saad F: The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis, 2009; 207: 318-327
102. Jones TH: Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab, 2010; 21: 496-503
103. Kelly DM, Jones TH: Testosterone: a metabolic hormone in health and disease. J Endocrinol, 2013; 217: R25-45
104. Ali S, Garcia JM: Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a minireview. Gerontology, 2014; 60: 294-305
105. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS: The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle, 2011; 2: 153-161